Market Overview

Aeterna Zentaris Wins FDA Special Protocol Assessment for Phase 3 Registration Trial in Endometrial Cancer with AEZS-108

Related AEZS
UPDATE: H.C. Wainwright Initiates Coverage On AEterna Zentaris
Morning Market Losers

Aeterna Zentaris Inc. (NASDAQ: AEZS) today announced that it has reached an agreement with the U.S. Food and Drug Administration ("FDA") on a Special Protocol Assessment ("SPA") for an upcoming Phase 3 registration trial in endometrial cancer with its doxorubicin peptide conjugate, AEZS-108. The SPA agreement states that the proposed trial protocol design, clinical endpoints and planned analyses are acceptable to the FDA to support a regulatory submission.

Study Design

This will be an open-label, randomized, multicenter Phase 3 trial conducted in North America and Europe, comparing AEZS-108 with doxorubicin as second line therapy for locally-advanced, recurrent or metastatic endometrial cancer. The trial will involve approximately 500 patients and the primary efficacy endpoint is improvement in median Overall Survival.

About Special Protocol Assessments ("SPA")

The SPA process is a procedure by which the FDA provides official evaluation and written guidance on the design and size of proposed protocols that are intended to form the basis for a Biologics License Application ("BLA") or New Drug Application ("NDA"). Final marketing approval depends on the results of efficacy, the adverse event profile and an evaluation of the benefit/risk of treatment demonstrated in the Phase 3 trial.

Posted-In: News FDA

 

Related Articles (AEZS)

Around the Web, We're Loving...

Get Benzinga's Newsletters